Ann: Notification of upcoming expiry of Unlisted Options, page-80

Transcript from video. This is really interesting.

right and i' I'd highlight something

5:29

from previous discussions that you and I

5:30

have had publicly as well the big

5:32

opportunity here is China ordinarily one

5:34

needs to jump through certain Hoops to

5:36

get into the Chinese market you've

5:37

already had um uh some feedback from uh

5:40

China's answer to the FDA that they

5:42

would be happy with the data you've

5:43

already got plus add in some Chinese

5:45

patients on top of that so we could be

5:47

talking um a much easier path to

5:50

approval in China than a lot of other

5:52

drug developers have yeah that's right

5:54

so when we look at the the global

5:55

opportunity we think us is probably up

5:57

50% so it's the biggest opportunity but

5:59

to your point china has a really large

6:02

kidney issue kidney problem and so uh

6:05

they're Desperately Seeking treatments

6:07

for kidney disease in China One of the

6:10

key advantages we had when we went to

6:11

talk to the nmpa which is the FDA

6:14

equivalent in in China is that they have

6:16

confirmed that the study that we're

6:18

doing at the moment could be appropriate

6:20

for approval in China as well so no need

6:23

for a secondary or independent study

6:26

after this one this could be it for all

6:27

of the territories us Europe and China